Concerns about TD* or FTC resistance
Overall, the risk of developing TD* or FTC resistance among participants on PrEP is low 9. According to a World Health Organization (WHO) meta-analysis of HIV resistance data from randomised clinical trials of PrEP, participants on PrEP versus placebo who started PrEP at the time of acute HIV infection had a higher risk of developing resistance, with more cases of resistance developing to FTC than to TD*. Only a few TD* or FTC mutations were recorded among participants who seroconverted after randomisation into clinical trials 9. Similar findings were reported in a more recent review of clinical trials and case reports of HIV resistance occurring in the PrEP setting 10. Mathematical modelling shows that the number of HIV-1 infections that would be averted by PrEP greatly exceeds the number of drug-resistant infections that could occur 11.
Acknowledgement of Country